Short answer: In the Yorvipath label's 26-week placebo-controlled trial, the most common side effects were injection site reactions (39% vs 5% on placebo), dizziness or blood pressure drops on standing (28% vs 0%), headache (21% vs 10%), diarrhea (10% vs 5%), back pain and high blood calcium (8% each vs 0%). There is no boxed warning; the label warns about serious high and low calcium and allergic reactions.
What Yorvipath is approved for: Yorvipath is a parathyroid hormone analog (PTH(1-34)) approved to treat hypoparathyroidism (low parathyroid hormone) in adults. It was not studied for sudden low parathyroid hormone right after surgery, and its dose-adjustment plan was only tested in adults whose albumin-corrected blood calcium was first brought to at least 7.8 mg/dL with calcium and active vitamin D (section 1).
Source
YORVIPATH (palopegteriparatide) injection, for subcutaneous use, prescribing information, Medication Guide and Instructions for Use. Ascendis Pharma. DailyMed, version published October 26, 2026. DailyMed setid a1fa23fd-c434-443e-9a17-5750578c8602
No. The current Yorvipath label has no boxed warning.
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Yorvipath.
| Adverse Reaction | YORVIPATH N=61 n (%) | Placebo N=21 n (%) |
|---|---|---|
| Injection site reactions | 24 (39) | 1 (5) |
| Vasodilatory signs and symptoms | 17 (28) | 0 |
| Headache | 13 (21) | 2 (10) |
| Diarrhea | 6 (10) | 1 (5) |
| Back pain | 5 (8) | 0 |
| Hypercalcemia | 5 (8) | 0 |
| Oropharyngeal pain | 4 (7) | 0 |
82 adults with hypoparathyroidism, 26-week blinded period. "Vasodilatory signs and symptoms" groups dizziness, dizziness on standing, blood pressure drops on standing, palpitations, fast heart rate on standing, near-fainting, fainting and vertigo.
| Measure | YORVIPATH N=61 | Placebo N=21 |
|---|---|---|
| Albumin-Corrected Serum Calcium >10.6 mg/dL, n (%) | 33 (54.1) | 2 (9.5) |
| Albumin-Corrected Serum Calcium >12 mg/dL, n (%) | 8 (13.1) | 0 (0) |
People with at least one calcium reading above the limit after starting. The above 10.6 mg/dL row includes those above 12 mg/dL.
High blood calcium with symptoms was reported in 8% of people on Yorvipath, all within the first 3 months after starting.
Reported after approval: allergic reactions, including anaphylaxis, angioedema (swelling under the skin), drug hypersensitivity and hives.
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
Allergic reactions. Anaphylaxis, angioedema and hives have been reported with parathyroid hormone analogs, including Yorvipath. Yorvipath is stopped if signs appear, and stopped permanently after a severe reaction.
Calcium swings from using two injections. The daily dose is given as one injection. Using two injections to reach the daily dose makes the total delivered dose less predictable, which can push calcium too high or too low.
Serious high blood calcium. High calcium needing a hospital stay has been reported. The risk is highest when starting or raising the dose. Calcium is checked 7 to 10 days after any dose change and at least every 4 to 6 weeks on a steady dose. Above 12 mg/dL, Yorvipath is held for at least 2 to 3 days.
Serious low blood calcium. Serious low calcium has been seen with parathyroid hormone products. The risk is highest when Yorvipath is stopped suddenly but can happen at any time, even on a steady dose.
Possible risk of osteosarcoma (bone cancer). Parathyroid hormone analogs caused osteosarcoma in rats, and cases have been reported in people taking teriparatide, though observational studies in humans have not shown a higher risk. Yorvipath is not recommended for people at higher risk, such as those with open growth plates, Paget's disease or other bone disease, unexplained high alkaline phosphatase, bone cancer or metastases, or past radiation to the skeleton.
Low blood pressure on standing. Dizziness, fast heartbeat, palpitations, near-fainting or fainting can happen. The label says symptoms can be managed by dosing at bedtime while reclining, and the first doses are given where the person can sit or lie down.
Digoxin. Because Yorvipath raises calcium, people on digoxin may be more prone to digoxin toxicity if calcium gets high, so calcium and digoxin levels are checked.
Who should not use it. People with a history of severe allergy to palopegteriparatide or any of Yorvipath's inactive ingredients.
From the Medication Guide that comes with Yorvipath:
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own. The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.